Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
1/6/2024
Menarini Group and Insilico Medicine Enter Global Deal for Novel KAT6 ...
1/6/2024
Novartis Acquires Renal Disease Firm SanReno Therapeutics
1/6/2024
Avenzo Thera Announces Global License of CDK2 Inhibitor from Allorion ...
1/6/2024
Boehringer Ingelheim partners with Ribo to develop new treatments for ...
1/6/2024
AstraZeneca and Allorion Strike Global Deal for Novel Preclinical-Stag...
1/6/2024
Roche and MediLink Therapeutics Enter Global Deal to Develop Next-gen ...
12/29/2023
China Issues the Implementation Plan for Saving Drug Resources and Cur...
12/29/2023
Financial-related Company News Digest (December 2023)
12/29/2023
Drug R&D and Product Registration News Digest December 2023 (4)
12/29/2023
Recent Official and Executive Moves
12/28/2023
CDE Issues the Technical Guidelines for Clinically Relevant Communicat...
12/28/2023
Astellas and Elpiscience Enter Research and License Deal for Novel Bis...
12/27/2023
Innovent and Xuanzhu Enter into Clinical Trial Collaboration for Combo...
12/27/2023
vTv Therapeutics Received Notice from Huadong Pharma for Termination o...
12/26/2023
China Issues Guidance Policy for High-Quality Development of Disease...
12/26/2023
LianBio Licenses Its Rights for NBTXR3 in China and Other Asian Marke...
12/26/2023
NMPA Issues the List of Reference Formulations for GQCE Studies (74th ...
12/26/2023
AstraZeneca to Buy Gracell to Further Cell Therapy Ambition Across Onc...
12/26/2023
NHC Issues the 3rd Batch of Its Catalogue of Encouraged Generic Drugs
12/26/2023
NMPA Solicits Comments on the Draft of GMP's Blood Product Appendix
12/25/2023
Qilu Pharma Acquires Hyperlipidemia Drug Candidate RBD7022 from Ribo...
12/25/2023
Biocytogen Enters into Antibody Deal with Ona Therapeutics to Develop ...
12/25/2023
InxMed Enters License Agreement with Escugen to Develop Next-Generatio...
12/25/2023
Oncoshot Teams Up with Zhejiang Ablaze Medicine to Drive Data-Powered ...
12/25/2023
GeneQuantum and BioMap Strikes Strategic Deal to Jointly Develop Next...
12/25/2023
NMPA Solicits Comments on the Implementation Doc for Provisions for QC...
12/25/2023
Mitsubishi Tanabe Sells Majority Stake of Chinese JV to Local Partner ...
12/25/2023
NHC Claims Occupational Health Improvements
(Free)
12/22/2023
Drug R&D and Product Registration News Digest December 2023 (3)
12/22/2023
CDE Solicits Comments on the Dossier Requirements for Marketing Regist...
Page:
34
/
38
Total number of articles:
1126
:
[First]
[<<]
[32]
[33]
[34]
[35]
[36]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit